the causal variant itself or a nearby marker with which it is tightly correlated. Until the advent of methods that enabled genomewide surveys of association, researchers were therefore obliged to direct their attention to specific candidate variants or genes of interest. 6 In retrospect, it is obvious that most such studies were seriously underpowered or focused on inappropriate candidates. 6 Nevertheless, by accruing data over the course of multiple studies, some genuine susceptibility variants were identified. Common coding variants in PPARG and KCNJ11 (each of which encodes a protein that acts as a target for classes of therapeutic agents widely used in diabetes management) were shown to have modest effects on the risk of type 2 diabetes. 7, 8 Resequencing of the gene encoding the melanocortin-4 receptor (MC4R) resulted in the identification of lowfrequency coding variants that explain approximately 2 to 3% of cases of severe obesity. 9 The third, and most successful, wave of discovery has been driven by systematic, large-scale surveys of association between common DNA sequence variants and disease. The first demonstration that unbiased discovery efforts could reveal new insights into the pathogenesis of type 2 diabetes resulted from identification of the association between type 2 diabetes and variants within TCF7L2 (encoding transcription factor 7-like 2, a protein not previously identified as a biologic candidate). 10 TCF7L2 has now been shown to modulate pancreatic islet function. 11 The number of loci for which there is convincing evidence that they confer susceptibility to type 2 diabetes started to grow in early 2007 with the publication of the first genomewide as- Signals are shown according to their location on each chromosome. Genes causing monogenic and selected syndromic forms of diabetes are shown to the left: genes implicated in maturity-onset diabetes of the young (red triangles) and those representing loci causal for other monogenic and syndromic forms of diabetes (green triangles). Common variants that have significant genomewide associations with multifactorial forms of diabetes are shown to the right (blue triangles); for these variants, the genes named within the triangles are indicative of signal position, but in most instances, formal proof that these are the specific genes responsible for the association is lacking.
sociation studies. [12] [13] [14] [15] [16] [17] [18] Together, these studies revealed six new associations, including variants near CDKAL1, CDKN2A, and CDKN2B (which encode putative or known regulators of cyclin-dependent kinases) and HHEX (which is transcribed into a homeobox protein implicated in beta-cell development). Typically each copy of a susceptibility allele at one of these loci is associated with a 15 to 20% increase in the risk of diabetes. Since then, the dominant approach to discovery has involved ever-larger aggregations of genomewide association data from multiple samples so as to improve the power to identify variants of modest effect: these studies have revealed more than 20 additional confirmed signals of susceptibility to type 2 diabetes [19] [20] [21] [22] (Table 1 and Fig. 1 ). Though early studies were restricted to samples obtained from persons of European descent, genomewide association analyses conducted in other ethnic groups are now emerging. 23, 24, 29 The current total of approximately 40 confirmed type 2 diabetes loci includes variants in or near WFS1 (wolframin) and the hepatocyte nuclear factors HNF1A and HNF1B (genes that also harbor rare mutations responsible for monogenic forms of diabetes) 30-33 ; the melatonin-receptor gene MTNR1B (which highlights the link between circadian and metabolic regulation) [26] [27] [28] ; and IRS1 (encoding insulin-receptor substrate 1), one of a limited number of type 2 diabetes loci with a primary effect on insulin action rather than on secretion. 25 Genomewide association studies of genetic variants influencing body-mass index (BMI) and   LEPR   POMC   PCSK1   SIM1   MC4R   LEP   SEC16B   TMEM18   ETV5   GNPDA2   PCSK1   NCR3   BDNF   MTCH2   SH2B1   FTO   MC4R  NRXN3   PTER   NPC1   MAF   LYPLAL1   BDNF   SNRPN  SH2B1   TNNI3K   PTBP2   SDCCAG8   POMC   FANCL   LRP1B   CADM2   SLC39A8   ZNF608   LRRN6C   TUB   MTIF3   HMGCR   MAP2K5   GPRC5B   GIPR  TMEM160   HOXC13   ITPR2   ZNRF3   NFE2L3  VEGFA   LY86   RSPO3   CPEB4   STAB1   ADAMTS9   GRB14  PIGC   TBX15   NEGR1   TFAP2B   HMGA1  MSRA   FAIM2   KCTD15   1   14  15  16  17  18  19  20  21 Signals are shown according to their location on each chromosome. Genes causing monogenic and selected syndromic forms of obesity (red triangles) are shown to the left. Common variants that have significant genomewide associations with BMI or multifactorial obesity are shown to the right: loci implicated in BMI or weight variation at the population level (solid blue triangles), additional loci identified in case-control analyses of extreme obesity (open blue triangles), and variants identified primarily because of their association with waist circumference or waist-to-hip ratio (solid green triangles). For the variants shown to the right, the genes named within the triangles are indicative of signal position, but in most instances, formal proof that these are the specific genes responsible for the association is lacking.
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obesity have been similarly productive, with three main strategies being adopted ( 
From Gene s t o Cl inic a l Pr ac t ice
Despite the growing number of loci discovered, the contribution of genetic discoveries to the clinical management of diabetes and obesity remains limited to the small proportion of cases with monogenic forms of disease. What, then, are the obstacles impeding the clinical translation of the scores of multifactorial variants now defined?
The first is the modest effect size of the implicated variants. The common variants with the greatest effects on the risk of type 2 diabetes (TCF7L2 in Europeans, KCNQ1 in Asians) result in lifetime prevalence rates that are, in persons carrying two copies of the risk allele, roughly double those seen in persons with none. 10, 23, 24 The association signal at FTO accounts for less than 0.5% of the overall variance in BMI, equivalent to a difference of 2 to 3 kg between adults homozygous for the risk allele and those homozygous for the alternative allele. 13 Most other variants associated with type 2 diabetes and BMI have effects considerably smaller than these. More detailed analysis of the associated regions may reveal that some of these associations are driven by causal variants with larger effects, although empirical evidence supporting this assertion is limited. 22 In contrast, the mutations underlying monogenic forms of diabetes and obesity have far more dramatic clinical consequences: in pedigrees segregating these conditions, knowing whether a family member has inherited a given causal allele generally allows for the confident prediction of disease status.
A second obstacle to the translation of variants implicated in multifactorial forms of diabetes and obesity relates to the speed with which risk-allele discovery has led to an improved understanding of the biologic basis of disease. Most alleles implicated in monogenic and syndromic forms of diabetes and obesity alter the coding sequence and therefore have dramatic Glossary Allele: One of two or more versions of a genetic sequence at a particular location in the genome.
Association analysis: An approach to susceptibility-gene discovery that relies on identifying genetic variants whose allele frequencies are robustly correlated with either disease status or the level of a trait of interest.
Candidate-gene study: An approach to susceptibility-variant discovery that focuses on genetic analysis restricted to one or more candidate genesgenes that have typically been selected on the basis of a perceived match between their known or presumed functions and the biologic characteristics of the disease in question.
Coding variant:
The part of the genomic DNA sequence that encodes proteins (consisting of approximately 1.5% of the total human genome).
Genomewide association study: An approach used in genetics research to look for associations between many (typically hundreds of thousands) of specific genetic variations (most commonly, single-nucleotide polymorphisms) and particular diseases or traits.
Homozygous: Having the same allele on both chromosomes at a particular location in the genome.
Linkage analysis: An approach to susceptibility-gene discovery that relies on matching family-level patterns of segregation of the disease of interest with genetic markers of known location.
Monogenic disease:
Genetic disease attributable to variants with large effects on disease status. Because of the high penetrance of such variants, the disease typically cosegregates in a classic mendelian fashion (e.g., dominant or recessive).
Next-generation sequencing: DNA sequencing that harnesses advances in miniaturization technology to simultaneously sequence multiple areas of the genome rapidly and at low cost.
Noncoding variant:
A DNA sequence variant that is located outside the coding sequence; some are likely to be involved in gene regulation.
Syndromic disease:
Syndromes are characterized by the concomitant occurrence of several distinct clinical features. In syndromic forms of diabetes such as Wolfram's syndrome, a rare mutation of large effect leads not only to diabetes but also to a diversity of other features including optic atrophy and deafness.
Transcript: An RNA sequence resulting from transcription of a DNA sequence (often a gene).
Copyright © 2010 Massachusetts Medical Society. All rights reserved. and largely predictable effects on the function of the gene. The use of molecular diagnostics to derive clinically useful prognostic and therapeutic information relies on this relatively straightforward assignment of functional significance. In multifactorial disease, however, most susceptibility variants lie outside the coding regions of genes and are assumed to influence transcript regulation rather than gene function. Characterization of the downstream consequences of these "noncoding" variants is difficult, given our rudimentary knowledge of the mechanics of gene regulation. Detailed functional studies are required to translate these genomic "signposts" into biologic knowledge that can spur translational development, and there have been relatively few successes. 48 Indeed, at most susceptibility loci, it remains far from clear even which transcripts mediate the susceptibility effects that have been observed.
The time required to achieve clinical translation is often underestimated, 49 and most of the discoveries in multifactorial disease have simply been too recent for their full translational potential to be realized. That potential lies in three main areas: the characterization of disease mechanisms that provide new targets for treatment and prevention, improved risk prediction and differential diagnosis, and personalized treatment and prevention.
From Gene t ic s t o Biol o gy
An improved understanding of pathophysiology achieved through genetic discovery provides new opportunities for treatment, diagnosis, and monitoring. Studies of risk variants for type 2 diabetes in healthy populations have shown that most variants act through perturbation of insulin secretion rather than insulin action, establishing inherited abnormalities of beta-cell function or mass (or both) as critical components of the progression to type 2 diabetes (Fig. 3) . 22 Type 2 diabetes results when pancreatic beta cells are unable to secrete sufficient insulin to maintain normoglycemia, typically in the context of increasing peripheral insulin resistance. The beta-cell abnormalities fundamental to type 2 diabetes are thought to include both reduced beta-cell mass and disruptions of beta-cell function. Insulin resistance can be the consequence of obesity or of obesity-independent abnormalities in the responses of muscle, fat, or liver to insulin. Examples of susceptibility variants that, given current evidence, are likely to influence predisposition to type 2 diabetes by means of each of these mechanisms are shown.
An interactive graphic is available at NEJM.org
The some susceptibility variants associated with type 2 diabetes is available at NEJM.org.) At loci for which there is evidence of a primary effect driven by abnormalities of insulin action, both obesitydependent and obesity-independent mechanisms are involved (Fig. 3) . 22 As described above, it is not always easy to link association signals to specific transcripts, but some of the genes more confidently assigned to type 2 diabetes susceptibility -TCF7L2, SLC30A8, and CDKN2A and CDKN2B -relate to Wnt signaling, zinc transport, and cellcycle regulation, respectively, suggesting that these functions have roles in the maintenance of normal islet function. 22, 51 Beyond that, efforts to identify key processes in the pathogenesis of type 2 diabetes -for example, by showing that genes encoding members of particular pathways are overrepresented at susceptibility loci -have not been particularly rewarding. 22 Either type 2 diabetes is highly heterogeneous, or those fundamental disease processes are poorly captured by existing biologic knowledge.
Efforts to achieve therapeutic modification of weight have had little success. The identification of new pathways amenable to safe and effective weight manipulation would be a valuable "deliverable" from genetic-discovery efforts. However, the transition from association signal to causal mechanism has not been straightforward, especially when the disease involves tissues as inaccessible to direct study as the human hypothalamus. Consider the example of FTO. 13 Although the association signal maps to a clearly defined region of the gene, and the effect is comparatively large, there is still some doubt as to whether FTO itself is responsible for the weight phenotype, rather than one of the nearby genes such as RPGRIP1L (also expressed in the hypothalamus, with responses to alterations in nutritional and hormonal status similar to those of FTO 52 ). Studies of mice with disruptions of Fto sequence 53, 54 are consistent with the hypothesis that FTO mediates the BMI effect in humans, whereas studies of human FTO mutations have been less clear-cut. 55, 56 Notwithstanding these data, the story emerging from the growing number of loci supports the view of overall obesity as a disease of hypothalamic dysregulation. 37, 43 In contrast, variation in patterns of fat distribution is associated with variants within genes that influence adipocyte development and function. 40, 41, 44 How best to use this information to effect early translation into new therapeutic or preventive approaches remains uncertain.
One characteristic of metabolic disease is the cluster of traits referred to as the metabolic syndrome. However, the genetic evidence to date provides limited support for the metabolic syndrome as a defined pathophysiological entity, perhaps indicating that this clustering is driven by environmental factors. Though BMI-associated variants such as FTO modulate the risk of type 2 diabetes and hyperlipidemia, 57 and loci altering lipid levels have secondary effects on the risk of coronary artery disease, 58, 59 there is little suggestion that the variants implicated in individual components of the metabolic syndrome overlap. At some loci, the patterns of association actually run counter to the broader correlative patterns of the metabolic syndrome. At the glucokinase regulator gene GCKR, for example, one common variant allele increases triglyceride levels yet lowers glucose levels. 15, 60, 61 The complexity of the relations that can exist at the genetic level between closely related phenotypes is further illustrated by the observation that alleles associated with similar degrees of fasting hyperglycemia in healthy populations have highly variable effects on the risk of type 2 diabetes later in life. 20 
Pr edic t ion a nd Differ en t i a l Di agnos t ic s
In cases of monogenic disease, genetic information can provide powerful diagnostic and predictive value for selected patients. Since subtypes of monogenic diabetes and obesity vary in their prognostic implications and therapeutic recommendations, a definitive molecular diagnosis is an important component of clinical management (Table 3) . 3, 62 To date, the use of molecular diagnostic tools has been limited by the expense of using conventional sequencing technologies to screen known causal genes for mutations that are often specific to a given family. Next-generation sequencing technologies are likely to be transformative in the medium term, though distinguishing pathogenic mutation from incidental variation will remain a challenge. In the meantime, improved biomarkers of diabetes subtypes that enable the more precise targeting of diagnostic resequencing would be valuable. ample, patients with maturity-onset diabetes of the young caused by HNF1A mutations have recently been shown to have C-reactive protein (CRP) levels well below those of patients with other subtypes of diabetes, suggesting that CRP could form the basis of a useful diagnostic test. 63 This observation also exemplifies the early translation of genetic discoveries, since it came directly from genomewide association studies showing that CRP levels are influenced by common variants near HNF1A.
The effect sizes of the known, common variants influencing the risk of type 2 diabetes and variation in adult BMI are modest, and the proportion of overall predisposition explained is small: approximately 5 to 10% for type 2 diabetes and 1% for BMI. 22, 43 As a result, the ability to perform individual-level prediction with respect to these traits is limited. By combining data from multiple loci, one can identify persons who have inherited especially high or low numbers of risk alleles: the risk of type 2 diabetes differs by a factor of approximately 4 between persons in the top 1% and those in the bottom 1% of the "risk-score" distribution. [64] [65] [66] [67] However, the risk profiles of many such persons are already discernible on the basis of conventional risk factors (e.g., BMI or family history), and there is limited evidence to suggest that information about genetic predisposition can be used effectively to guide the modification of long-term behavior. The discriminative accuracy of genetic profiling of known type 2 diabetes risk variants (as measured by means of receiver-operatingcharacteristic curves) is only approximately 60%, [64] [65] [66] [67] well below the threshold required for clinical usefulness and the degree of prediction achievable on the basis of nongenetic risk factors. 68 Furthermore, estimates of risk can depend crucially on exactly which variants are included in the risk profile. 69 The key to improved performance will be the identification of risk variants with greater effect sizes than those discovered so far. Since existing genomewide association studies have most likely captured any common variants of large effect, the search is now focused on less-common variants.
A person's risk of type 2 diabetes or obesity reflects the joint effects of genetic predisposition and relevant environmental exposures. Efforts to determine whether these genetic and environmental components of risk interact (in the statistical sense that joint effects cannot be predicted from main effects alone) 70 face challenges associated with measuring relevant exposures (diet and physical activity being notoriously difficult to estimate) and the effect of imprecision on statistical power. 71 Although claims that statistical interactions reflect shared mechanisms (i.e., that the interacting factors act through the same pathways) are probably overstated, understanding the relative contributions of genetic and environmental components to risk is important. After all, environmental factors can be modified more readily than genetic factors. Genetic discoveries have provided a molecular basis for the clinically useful classification of monogenic forms of diabetes and obesity. 3, 4 Will the same be true for the common forms of these conditions? Probably not: as far as the common variants are concerned, each patient with diabetes or obesity has an individual "barcode" of susceptibility alleles and protective alleles across many loci. It is possible to show that the genetic profiles of lean subjects with type 2 diabetes and obese subjects with type 2 diabetes are not identical, but these differences appear to be inadequate for clinically useful subclassification. 22, 72 If efforts to uncover less prevalent, higher-penetrance alleles are successful, more precise classification of disease subtypes may become possible, particularly if genetic data can be integrated with clinical and biochemical information. For example, in persons presenting with diabetes in early adulthood, there are several possible diagnoses: various subtypes of maturity-onset diabetes of the young or mitochondrial diabetes, for example, as well as type 1 or type 2 diabetes. Assigning the correct diagnosis has both prognostic and therapeutic benefits for the patient (Table 3) .
Ta rge ted T r e atmen t a nd Pr e v en t ion
Recommended therapies for the various subtypes of diabetes differ (Table 3) . 3, 4, 62, [73] [74] [75] In monogenic forms of diabetes, at least, genetic testing already drives the choice of therapy. For example, in patients who have maturity-onset diabetes of the young due to mutations in the gene encoding glucokinase (GCK), the hyperglycemia is mild and stable, the risk of complications is low, and dietary management is often sufficient. In contrast, in patients who have maturity-onset diabetes of the young due to mutations in HNF1A, the disease follows a more aggressive course, with a greater risk of severe complications, but is particularly responsive to the hypoglycemic effects of sulfonylureas. 62, 73 Most children with neonatal diabetes have mutations in KCNJ11 or ABCC8, adjacent genes that jointly encode the beta-cell ATP-sensitive potassium channel that mediates glucose-stimulated insulin secretion and is the target of sulfonylureas. In such children, treatment with sulfonylureas has proved more effective and convenient than the lifelong insulin therapy previously considered the default option. 74, 75 In children with severe obesity due to profound leptin deficiency, exogenous leptin therapy is lifesaving. 76 As yet, there are insufficient genetic data to support management decisions for common forms of type 2 diabetes and obesity. 77 Although the TCF7L2 genotype is associated with variation in the response to sulfonylurea treatment, 78 the effect is too modest to guide the care of individual patients. For the time being, the contribution of genetic information to therapy is most likely to come through the drug-discovery pipeline. Information from genetic studies could be used to identify new targets for pharmaceutical intervention that have validated effects on physiological characteristics, to provide information about new and existing targets (e.g., clues about the long-term safety of pathway intervention), 32 and to characterize high-risk groups to enable more efficient clinical trials of agents designed to reduce the progression of type 2 diabetes or obesity or the risk of complications.
Sum m a r y
Given the substantial time it takes to translate basic biomedical discoveries into clinical tools, 49 any current assessment of the clinical value of recent advances in the genetic basis of common diseases is probably an underestimate. An improved understanding of fundamental disease mechanisms is already emerging; this will underpin future therapeutic advances. But the expansion of personalized medicine beyond monogenic forms of disease awaits a more complete description of predisposition. The boundaries of personalized medicine will be much clearer in a few years, after large-scale genomewide resequencing efforts (now under way) provide a systematic, comprehensive description of the relations between genome sequence variation and major clinical phenotypes. 
